SCHEMBL2575170

SCHEMBL2575170

CC(=O)OC[C@H]1O[C@@H](n2c(Cl)nc3ncnc-3c2Cl)[C@H](OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
LMNA P02545 3/20 0.54
MAPT P10636 3/20 0.54
TP53 P04637 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.47
THRB P10828 1/20 0.47
HIF1A Q16665 1/20 0.47
PRKAB2 O43741 1/20 0.44
PRKAG1 P54619 1/20 0.44
PRKAA2 P54646 1/20 0.44
PRKAA1 Q13131 1/20 0.44
PRKAG3 Q9UGI9 1/20 0.44
PRKAG2 Q9UGJ0 1/20 0.44
PRKAB1 Q9Y478 1/20 0.44
GALR3 O60755 1/20 0.43
PRKCA P17252 1/20 0.42
AKT1 P31749 1/20 0.42
PTK2 Q05397 1/20 0.42
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2577254 0.92 LMNA (0.47) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL2575304 0.89 ALDH1A1 (0.49) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL2584021 0.87 LMNA (0.42) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL10899679 0.85 LMNA (0.60) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL2585674 0.85 LMNA (0.60) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL2579907 0.82 ALDH1A1 (0.47) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL2585159 0.81 LMNA (0.42) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL2587636 0.80 ALDH1A1 (0.38) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL14780131 0.80 ALDH1A1 (0.59) ALDH1A1LMNAMAPTTP53TDP1
SCHEMBL2578101 0.79 LMNA (0.45) ALDH1A1LMNAMAPTTP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2018-10-16 US disclosed
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION GILEAD SCIENCES, INC. (US) 2014-02-27 US disclosed
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PHARMASSET, INC. 2011-11-03 US disclosed
EP-2251015-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation Pharmasset, Inc. (US) 2010-11-17 EP disclosed
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation PHARMASSET, INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION SLC29A1, PNP, SLC29A2 ALDH1A1 1466/4885LMNA 1019/4885MAPT 2647/4885
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PNP, ALPP, XDH ALDH1A1 2416/4885LMNA 694/4885MAPT 3743/4885
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, SLC29A2, PNP ALDH1A1 1128/4885LMNA 821/4885MAPT 2453/4885
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, PNP, SLC29A2 ALDH1A1 1367/4885LMNA 1076/4885MAPT 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.